Sensipar Is $8.10 Per 30 Mg; A “Fair Price” For A “Major Advance,” Amgen Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The chronic kidney treatment is priced at a premium to Genzyme’s Renagel and vitamin D, but Amgen does not see Sensipar as a direct competitor. The 60 mg and 90 mg tablets will be priced on a linear scale.
You may also be interested in...
Amgen Sensipar Approved; Target U.S. Market At Least 300,000 Patients
Cinacalcet is indicated for the treatment of hyperparathyroidism associated with kidney disease and hypercalcemia in parathyroid cancer patients.
Barr’s Expanded Thalidomide ANDA Could Increase Likelihood Of A Marketed Generic
Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.
User Fee Deal For Ad Review Funds Stems From PhRMA DTC Principles
A draft agreement between industry and FDA that would assess user fees for "advisory review" of broadcast direct-to-consumer ads prior to initial public dissemination had its genesis in the Pharmaceutical Research & Manufacturers of America's DTC guiding principles